• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

FDA/NIH/WHO Public Workshop: Immune Correlates of Protection Against Influenza A Viruses in Support of Pandemic Vaccine Development

December 10 and 11, 2007

FDA's Center for Biologics Evaluation and Research, in cooperation with the National Institutes of Health's Division of Intramural Research within the National Institute of Allergy and Infectious Diseases and the World Health Organization, held this public workshop which included discussions on: (1) Current knowledge regarding correlates of protection against seasonal influenza, (2) immune responses to avian influenza infections and vaccines for novel influenza viruses in humans, (3) assays to evaluate vaccine immunogenicity, and (4) evaluation of avian influenza vaccine efficacy. The goals of the public workshop were to: (1) Identify the gaps in our knowledge and abilities in addressing the unique challenges encountered in the development and evaluation of vaccines intended to protect against pandemic influenza, and (2) facilitate implementation of a global research agenda to improve efficacy assessment of pandemic influenza vaccines.


Agenda

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007, Vaccine 26 (2008) 4299–4303 (PDF - 196 KB)

December 10 Transcripts
December 11 Transcripts

December 10 Webcast (Captioned) (RealPlayer)
December 11 Webcast (Captioned) (RealPlayer)
  Download Free RealPlayer

Workshop Presentations

Day 1 - December 10, 2007

Introduction

Session 1. Correlates of protection against seasonal influenza

Session 2. Immune responses to avian influenza infections and vaccines for novel influenza viruses in humans

Summary of Day 1 (PDF - 26 KB) - Robert B. Couch, MD

Day 2 - December 11, 2007

Session 3. Assays to evaluate vaccine immunogenicity

Session 4. Evaluation of avian influenza vaccine efficacy

Panel Discussion (PDF - 18 KB)